We previously reported that acute and selective activation of GABA-releasing parafacial zone (PZ Vgat ) neurons in behaving mice produces slow-wave-sleep (SWS), even in the absence of sleep deficit, suggesting that these neurons may represent, at least in part, a key cellular substrate underlying sleep drive. It remains, however, to be determined if PZ Vgat neurons actively maintain, as oppose to simply gate, SWS. To begin to experimentally address this knowledge gap, we asked whether activation of PZ Vgat neurons could attenuate or block the wakepromoting effects of two widely used wake-promoting psychostimulants, armodafinil or caffeine. We found that activation of PZ Vgat neurons completely blocked the behavioral and electrocortical wake-promoting action of armodafinil. In some contrast, activation of PZ Vgat neurons inhibited the behavioral, but not electrocortical, arousal response to caffeine. These results suggest that: (1) PZ Vgat neurons actively maintain, as oppose to simply gate, SWS and cortical slow-wave-activity; (2) armodafinil cannot exert its wake-promoting effects when PZ Vgat neurons are activated, intimating a possible shared circuit/molecular basis for mechanism of action; (3) caffeine can continue to exert potent cortical desynchronizing, but not behavioral, effects when PZ Vgat neurons are activated, inferring a shared and divergent circuit/ molecular basis for mechanism of action; and 4) PZ Vgat neurons represent a key cell population for SWS induction and maintenance.
INTRODUCTION
The neuronal mechanisms controlling slow-wave-sleep (SWS, also called NREM sleep) remain incompletely understood. In a recent series of studies, we uncovered a delimited node of GABAergic SWS-promoting neurons in the rostral medullary parafacial zone (PZ Vgat ), and showed that acute and selective activation of these neurons potently drove SWS, even during the early active period when sleep drive is minimal (Anaclet et al, 2014; Anaclet et al, 2012) . Interestingly, this induced SWS shared several key characteristics with physiologic 'rebound' sleep, for example, increased sleep time, consolidation and elevated cortical slow-wave activity [SWA; (Anaclet et al, 2014) ], suggesting that PZ Vgat neurons may also play a key role in sleep homeostasis. The synaptic and circuit basis by which PZ Vgat neurons produce sleep remains unresolved, although a functional polysynaptic pathway from the PZ to the cortex, via the wake-promoting parabrachial nucleus and basal forebrain (Anaclet et al, 2015; Fuller et al, 2011) , has been implicated (Anaclet et al, 2014) .
It nevertheless remains to be clarified whether PZ Vgat neurons are actively involved in maintaining SWS, as opposed to simply triggering or passively gating SWS. Our working hypothesis is that activation of PZ Vgat neurons produces and maintains cortical synchronization and SWS through both inhibition of wake-promoting circuitries (passive gating) as well as via an as yet unknown active mechanism.
To begin to experimentally address this hypothesis, we asked whether activation of PZ Vgat neurons could attenuate or block the wake-promoting and cortical desynchronizing effects of two widely used wake-promoting psychostimulants, armodafinil and caffeine. We predicted that the SWS induced by activation of PZ Vgat neurons would be strongly attenuated, possibly even blocked, by administration of armodafinil or caffeine if PZ Vgat neurons function simply to 'gate' SWS. If, on the other hand, PZ Vgat neurons actively maintain SWS, we would predict that their sustained activation would counteract the wake-promoting effects of armodafinil and caffeine. We chose to use both armodafinil and caffeine on the basis that, while these compounds are both wake-promoting, they are also largely divergent in their wake-promoting mechanism of action. For example, modafinil is a weak, but apparently very selective, dopamine transporter (DAT) inhibitor, and appear to activate multiple wake-promoting circuits (Fiocchi et al, 2009; Lin et al, 1996; Scammell et al, 2000) . (± )modafinil (modafinil) and its R-enantiomer, armodafinil, may also inhibit the sleep-promoting ventrolateral preoptic nucleus (VLPO) (Cornil et al, 2002; Gallopin et al, 2004; Scammell et al, 2000) , although lesions of the VLPO do not block the wakepromoting effects of armodafinil (Vetrivelan et al, 2014) . By contrast, caffeine is an adenosine A1 and A2A receptor antagonist and it has been shown that A2A receptors in the shell region of the nucleus accumbens are a critical substrate for caffeine's wake-promoting action (Lazarus et al, 2011) . Both modafinil and caffeine do, however, promote dopamine signaling (Galvalisi et al, 2017; Nall et al, 2016; Volkow et al, 2015; Wisor, 2013) .
MATERIALS AND METHODS

Animals
Adult male Vgat-IRES-cre mice (Vong et al, 2011) and noncre-expressing littermate mice (8-12 weeks, 20-25 g; n = 46) were used in this study. Mice were bred at our animal facility and underwent genotyping both before and after experiments. All procedures were approved by the Institutional Animal Care and Use Committee of Beth Israel Deaconess Medical Center.
Surgery
Naive mice were anesthetized with ketamine/xylazine (100 and 10 mg/kg, respectively, intraperitoneal (IP)) and then placed in a stereotaxic apparatus. To selectively express the hM3Dq receptors in GABAergic (VGAT+) neurons of the PZ, we placed bilateral injections of an adeno-associated viral (AAV; serotype 10) vector expressing the hM3Dq receptor in a cre-dependent configuration (hSyn-DIO-hM3Dq-mCherry-AAV; (Anaclet et al, 2014) ) into the PZ (coordinates: Antero-Posterior = −5.3 mm, Lateral = ± 0.7 mm, Dorsoventral = − 3.4 mm, as per the mouse atlas of Paxinos and Watson (Paxinos and Franklin, 2001) ) of Vgat-IRES-cre mice (PZ ). As vector injection controls, we injected the same viral vector into the PZ of non-cre expressing littermate mice (PZ Vgat-wt ). Injections of the viral vector (60 nl) into the PZ of these mice were performed using a compressed air delivery system as previously described (Anaclet et al, 2010) . After injections, mice were implanted with four EEG screw electrodes (Pinnacle Technology Inc.) and two flexible electromyogram (EMG) wire electrodes (Plastics One), previously soldered to a 6-pin connector (Pinnacle Technology Inc.) and the assembly was secured with dental cement. The scalp wound was closed with surgical sutures and the mouse was kept in a warm environment until resuming normal activity as previously described (Anaclet et al, 2015) .
Sleep-Wake Monitoring
Three weeks after surgery, the mice were housed individually in transparent barrels in an insulated sound-proofed recording chamber maintained at an ambient temperature of 22 ± 1°C and on a 12 h light/dark cycle (lights-on at 07:00 A.M., Zeitgeber time: ZT0) with food and water available ad libitum. Mice were habituated to the recording cable for 5-7 days before starting polygraphic recording. Cortical EEG (ipsilateral fronto-parietal leads) and EMG signals were amplified and digitalized with a resolution of 500 Hz using Vital recorder (Kissei, Japan). Mice were recorded for 24 h baseline period followed by intraperitoneal injections of saline (control injection), Clozapine-N-oxide (CNO, Sigma-Aldrich; 0.3 mg/kg in saline), armodafinil (Cephalon; 90 and 180 mg/kg in saline), caffeine (Sigma; 5 and 20 mg/kg in saline), CNO plus armodafinil and CNO plus caffeine. Injections were performed at 10:00 A.M. (ZT3, light period, time of high sleeping drive), in a randomized cross-over design, with each injection separated by a 3-5 day washout period. In each experiment, recordings were simultaneously made from an equal number (batches of 2-4) of PZ and PZ Vgat-wt mice.
Sleep Scoring and Analysis
Using SleepSign for Animal (Kissei, Japan) and with assistance of spectral analysis using fast Fourier transform, polygraphic records were visually scored by 10 s epochs for wakefulness (W), slow-wave-sleep (SWS), and rapid eye movement (REM) sleep. The percentage of time spent in wake, SWS and REM sleep were summarized for each group and each condition. The latency to SWS and REM sleep are defined as the time between the end of the injection and the onset of the first SWS episode lasting 420 s and the first REM sleep episode lasting 410 s. Recordings were scored again in 5 s epochs to allow for performance of an EEG power spectrum analysis. On the basis of visual and spectral analysis, epochs containing artifacts occurring during active wake (with large movements) or containing two vigilance states were visually identified and omitted from the spectral analysis. Recordings containing wake artifacts during 420% of the time were removed from the spectral analysis. EEG power spectra were computed for consecutive 5 s epochs within the frequency range of 0.5-120 Hz using a fast Fourier transform routine (FFT). The data were collapsed into 0.5 Hz bins. To determine the effect of injection on sleep-wake power spectra of PZ and PZ Vgat-wt mice, EEG power spectra were analyzed during the 1-3 h period of time post injection, starting 10 min after injection as CNO injection significantly affects SWS amount during 3 h post injection and SWS latency is no more than 10 min in PZ Vgat-hM3Dq mice (Anaclet et al, 2014) . The data were standardized by expressing each frequency bin as a percentage relative to the same bin in baseline condition from the same mouse and from the same time of the day (same Zeitgeber time). To analyze the EEG frequency bands, power bins were summed in δ: 0.5-5 Hz, θ: 5-9 Hz, α: 9-15 Hz, β: 15-30 Hz, low γ: 30-60 Hz and high γ: 60-120 Hz, and expressed in percentage of baseline power band, from the same circadian time.
Statistical Analysis
Statistical analysis was performed using Prism v6 (GraphPad Software, San Diego, CA, USA). Following confirmation that the data met the assumptions of the ANOVA model, twoway ANOVA followed by a post hoc Bonferroni test were used to compare the effects of the drug injection and time period on sleep-wake parameters or the effect of drug injection and power band on cortical EEG power density.
One-way ANOVA followed by a post hoc Bonferroni test were used to compare the effects of the drug injection on sleep latency. Sample size and power calculations were performed post hoc at http://www.biomath.info, using means and standard deviations derived from our analysis. The present study was sufficiently powered to detect effect sizes.
RESULTS
Activation of PZ
Vgat Neurons Blocks the Wake-Promoting Action of Armodafinil
To test whether activation of PZ Vgat neurons can block the arousal-promoting effects of armodafinil, nine mice expressing the excitatory hM3Dq receptor in PZ GABAergic Parafacial zone GABA neurons actively drive sleep C Anaclet et al neurons (PZ Vgat-hM3Dq mice) were injected in a randomized cross-over design with saline, CNO (hM3Dq ligand, 0.3 mg/ kg), armodafinil (90 mg/kg) or CNO+armodafinil (0.3 and 90 mg/kg, respectively; Figures 1 and 2). Treatment significantly affected SWS latency (one-way ANOVA, F(1.058,8.464) = 121.9, po0.0001). More specifically, and as previously shown, CNO injection significantly decreased and armodafinil significantly increased SWS latency (Figure 2a2 ). When CNO and armodafinil were co-injected, SWS latency was similar to CNO injection, indicating that the SWS-inducing action of PZ Vgat neurons is not affected by armodafinil at the dose of 90 mg/kg. REM sleep latency was significantly increased after CNO, armodafinil and CNO+armodafinil injections as compared with control injection (Figure 2a3 ).
Treatment significantly affected SWS amount during the two hour post-injection (two-way ANOVA, F(3,96) = 12.08, po0.0001; Figure 2bB ). CNO injection significantly increased SWS amount and armodafinil significantly increased wake amount as compared with control injection. Coinjection of CNO+armodafinil resulted in similar amounts of SWS as compared with CNO alone, indicating that the SWS-promoting action of PZ Vgat neurons is not affected by armodafinil at the dose of 90 mg/kg.
In some contrast to previous reports, a sleep rebound was observed during the dark period following armodafinil Amount of the vigilance stages during the 2 h post injection (10:00-12:00), the rest of the light period (12:00-19:00), the following dark period (19:00-7:00) and the first 3 h of the light period the next day (07:00-10:00), n = 9 mice. (c) Power spectrum changes (% ± SEM) over baseline during the 3 h post-injection period for vehicle injection as compared with the 1 h post-injection period for CNO, armodafinil and CNO+armodafinil administration, and the quantitative changes (% ± SEM) in power for the delta (δ: 0.5-5 Hz), theta (θ: 5-9 Hz), sigma (σ: 9-15 Hz), beta (β: 15-30 Hz), low gamma (lγ: 30-60 Hz) and high gamma (hγ: 60-120 Hz) frequency bands, n = 8 mice. Black star, po0.05 as compared with control injection; orange star, po0.05 as compared with CNO injection; light blue star, po0.05 as compared with armodafinil injection, two-way ANOVA corrected with a Bonferroni's multiple comparisons test. Parafacial zone GABA neurons actively drive sleep C Anaclet et al injection ( Figure 2bB ). Interestingly, a rebound of SWS but not REM sleep was also observed during the dark period following co-injection of CNO+armodafinil. Both wakefulness and SWS cortical EEG power spectra were affected by the treatment (Figure 2c ). Armodafinil significantly increased sigma, low and high gamma bands during wakefulness, confirming its cortical desynchronizing action. CNO-induced SWS was characterized by a significant increase of the delta band and a significant decrease of theta and low gamma bands. When CNO and armodafinil were co-injected, SWS cortical EEG was visually indistinguishable from CNO injection (Figure 2d ) with enhanced SWA and reduced theta rhythm (Figure 2cB ). Theta frequency band was similarly decreased after CNO and CNO+armodafinil, as compared with control injection. Interestingly, delta power was significantly more enhanced by co-injection of CNO +armodafinil as compared with CNO alone, indicating that armodafinil potentiates the cortical synchronizing action and SWA of PZ Vgat neurons. Finally, sigma frequency band, spindle frequency range, was significantly decreased by coinjection of CNO+armodafinil as compared with both CNO and control injection. Because spindles are more abundant during light sleep and SWA is a marker of SWS intensity/ quality, these results suggest that armodafinil potentiates the sleep-promoting action of PZ Vgat neurons. Armodafinil dose dependently enhanced wake amount in PZ Vgat-wt mice (Supplementary Table S1 ). Lack of nonspecific action and/or interaction of CNO and armodafinil was confirmed by the absence of sleep-wake change between control and CNO injections as well as between armodafinil and CNO+armodafinil injections in PZ Vgat-wt mice (Supplementary Table S1 & Supplementary Figure S1 ). These results confirm that CNO has no non-specific effect on sleepwake phenotype and does not affect the wake-promoting action of armodafinil in PZ Vgat-wt , in the absence of hM3Dq receptor.
Because it remains possible that a higher dose of armodafinil would be able to induce wakefulness even when PZ Vgat neurons are activated via the excitatory DREADDs, we tested whether or not armodafinil at a dose of 180 mg/kg would be sufficient to promote wakefulness when PZ Vgat neurons are activated, in PZ Vgat-hM3Dq mice. Similar results were observed between armodafinil 90 and 180 mg/kg (Figures 2 and 3) . At the high dose, the wake-promoting action of armodafinil lasted longer. As compared to their respective control injections, armodafinil (180 mg/kg) significantly increased wakefulness during 7 h following the injection (Figure 3aA ), whereas wakefulness was significantly increased during 5 h after 90 mg/kg dosing (Figure 2aA ). But activation of PZ Vgat neurons was still able to counteract the wake-promoting action of armodafinil and induced SWS during the 2 h following the co-injection of armodafinil (180 mg/kg)+CNO. Moreover, CNO was still able to increase SWS delta power band when co-injected with armodafinil 180 mg/kg (Figure 3bB ). These results indicate that activation of PZ Vgat neurons completely block the wake-promoting action of armodafinil. Interestingly, after the two first hours post armodafinil (180 mg/kg)+CNO injection, wakefulness was significantly increased as compared with both control and CNO injections, resulting in a similar amount of wakefulness as compared with armodafinil (180 mg/kg; Supplementary Table S2 ). This could be explained by the pharmacokinetics of CNO and armodafinil. CNO plasma concentration reaches a maximum 15 mins after intraperitoneal injection and is no longer detectable after two hours post-injection (Wess et al, 2013) . This observation suggests that PZ Vgat inhibition of wake-promoting action of armodafinil is reversible.
These results show that acute and specific activation of PZ Vgat neurons completely inhibits the wake-promoting action of armodafinil and this effect is reversible, not dose-dependent (up to 180 mg/kg) or due to a non-specific inhibition of armodafinil action in the brain.
Activation of PZ Vgat Neurons Counteracts the Wake-Promoting Action of Caffeine
To test if caffeine can induce wakefulness and block the sleep-promoting action of PZ Vgat neuronal activation, 15 PZ Vgat-hM3Dq mice were injected in a randomized cross-over design with saline, CNO (hM3Dq ligand, 0.3 mg/kg), caffeine (20 mg/kg) and CNO+caffeine (0.3 and 20 mg/kg, respectively; Figures 1 and 4a, b) . Treatment significantly affected SWS latency (one-way ANOVA, F(1.508,22.12) = 707.9, Parafacial zone GABA neurons actively drive sleep C Anaclet et al po0.0001). As previously shown, CNO injection significantly decreased and caffeine significantly increased SWS latency. When CNO and caffeine were co-injected, SWS latency was similar to control injection, indicating that caffeine, at the dose of 20 mg/kg, and activation of PZ Vgat neurons counteract each other, resulting in normal SWS latency following co-injection of CNO+caffeine (Figure 4a2 ). Treatment significantly affected sleep-wake amount during the 2 h post-injection (two-way ANOVA, F(9,168) = 20.03, po0.0001; Figure 4b ). CNO injection significantly increased SWS amount and caffeine significantly increased wake amount, as compared with control injection. Co-injection of CNO+caffeine resulted in similar amount of SWS as compared with control injection, further indicating that caffeine, at the dose of 20 mg/kg, and activation of PZ Vgat neurons counteract each other, resulting in normal SWS amount.
REM sleep latency was also affected by treatment (one-way ANOVA, F(1.126,15.76) = 15.47, p = 0.0009) and all treatments significantly delayed REM sleep onset as compared with control injection (Figure 4a3 ). As previously shown, after activation of PZ Vgat neurons, the deficit of REM sleep was not compensated by a rebound (Anaclet et al, 2014) . On the opposite, caffeine-induced REM sleep deficit during the 4 h following injection was compensated by a REM sleep rebound during the following 19-7 (dark) period. Interestingly, after co-injection of CNO+caffeine, mice displayed a REM sleep rebound similar to caffeine alone. This result suggests that caffeine, but not activation of PZ Vgat neurons, activates REM sleep homeostatic response and this response is not inhibited by activation of PZ Vgat neurons. As previously described with armodafinil injections, a SWS rebound was seen during the dark period following caffeine injection, at both doses (Figure 4bB & Supplementary  Table S2 ). Interestingly, a SWS rebound was seen during the dark period following CNO+caffeine injection even if the mice did not encounter a significant SWS deficit during the light period (Figure 4bB & Supplementary Table S2 ). Similar results were seen at the lower caffeine dosage, indicating that caffeine builds up SWS pressure independently of wake amount.
Both wakefulness and SWS cortical EEG power spectra were affected by the treatment (Figure 4c ). Caffeine significantly increased theta, sigma, low-and high-gamma bands during wakefulness, confirming its cortical desynchronizing action (Figure 4cA ). In contrast to armodafinil, co-injection of caffeine+CNO induced changes in the SWS cortical EEG and power distribution (Figure 4cB and d) . Caffeine inhibited PZ Vgat -induced slow-wave-activity, resulting in similar delta power between caffeine+CNO, control injection and baseline power. Moreover, caffeine+CNO-induced SWS was characterized by a significant increase in high-gamma frequency band as compared with both CNO and control injections. Finally, similar to armodafinil, sigma frequency band, spindle frequency range, was significantly decreased by co-injection of CNO+caffeine as compared with control injection. This indicates that even if activation of PZ Vgat neurons can induce SWS, caffeine can block PZ Vgat-hM3Dq -induced slow-wave-activity and spindle activity, while enhancing fast frequencies characteristic of cortical activation and wakefulness, during SWS, resulting in a poorer quality SWS.
Caffeine dose dependently enhanced wake amount in PZ Vgat-wt mice (Supplementary Table S3 ). A lack of nonspecific interactions between CNO and caffeine was confirmed by the absence of sleep-wake change between CNO and CNO+caffeine injections in control, PZ Vgat-wt mice (Supplementary Table S3 & Supplementary Figure S2) , indicating that CNO does not affect the wake-promoting action of caffeine in PZ Vgat-wt mice. To confirm that the inhibitory effect of caffeine (20 mg/kg) on PZ Vgat-hM3Dq induced SWS and its cortical EEG desynchronizing action was not due to non-specific action of high-dose caffeine, nine PZ Vgat-hM3Dq mice received injections of caffeine (5 mg/kg), CNO+caffeine (0.3 and 5 mg/kg, respectively), CNO (0.3 mg/kg) and saline as a control injection. At the dose of 5 mg/kg ( Figure 5 , Supplementary Table S2) caffeine significantly delayed SWS latency and REM sleep latency. Wakefulness was increased during the 2 h post caffeine (5 mg/kg) injection. CNO+caffeine counteracted each other, resulting in similar amount of SWS as compared with control during the 2 h post injection. Cortical EEG power spectral analysis revealed similar phenotypes as described for the high dose of caffeine (Figures 5b and 4c ). At the low dose, caffeine was still able to enhance sigma and high gamma bands as compared with control injection. Interestingly, when co-injected with CNO, caffeine (5 mg/kg) was still able to enhance cortical EEG high frequencies. These results suggest that activation of PZ VGAT neurons and caffeine counteract each other in a specific way.
DISCUSSION
In the present study, we show that activation of PZ Vgat neurons is capable of counteracting the potent wakepromoting properties of two psychostimulants, armodafinil and caffeine. This latter finding provides, to our knowledge, the first evidence that activation of a specific and delimited neuronal population is sufficient to induce and maintain SWS, even when the sleep-wake network is strongly pharmacologically biased toward cortical activation and wakefulness.
Technical Considerations
We undertook a myriad of control experiments to demonstrate that the observed phenotypes resulting from the chemogenetic and pharmacologic experiments were specific to the treatment. We first show that at the dose of 0.3 mg/kg, CNO does not influence baseline sleep-wake in PZ Vgat-WT (non-DREADDs expressing) mice. This result confirms that the EEG and behavioral phenotypes observed in this study were due to chemogenetic activation of PZ Vgat neurons via hM3Dq receptors as well as replicates previous results reported by our group (Anaclet et al, 2014) . We, moreover, show that both armodafinil and caffeine are potently wakepromoting and that both drugs dose-dependently increase wakefulness in mice, as have been previously reported (Parmentier et al, 2007) . In addition, administration of armodafinil or caffeine both significantly enhanced cortical desynchronization and fast frequencies during wakefulness, confirming that the absence of a waking phenotype observed following co-administration with CNO is due to activation of
PZ
Vgat neurons and not a deficit of a waking response to the psychostimulants in these mice. We also show that coinjection of CNO with armodafinil or caffeine did not affect the wake-promoting action of the two psychostimulants in control mice, indicating an absence of nonspecific effects of CNO on the circuit and/or molecular targets of armodafinil or caffeine. Hence, the sleep-wake changes described in PZ Vgat-hM3Dq mice are a direct result of the activation of PZ Vgat neurons. Also, when co-injected with CNO, both armodafinil and caffeine were able to exert a wakepromoting effect after the first 2-3 h post-injection, which is temporally coincident with CNO washout, that is, CNO is no longer detectable in the plasma (Wess et al, 2013) . This latter finding indicates that activation of PZ Vgat neurons by CNO is able to antagonize the wake-promoting action of the psychostimulants and that these effects are reversible. Taken together, results from our control studies provide high confidence that the observed phenotypes reflected neuronal activation/inhibition and not interactions or nonspecific actions of the drugs.
We chose to administer our wake-promoting compounds 3 h after lights-on (10:00 A.M., ZT3), which is a time of day that sleep drive is at or near its maximum in the mouse (Franken et al, 1999) . The rationale for administering our psychostimulants during the sleep period was that we wanted to maximize the magnitude of the wake-promotion following psychostimulant administration. We felt that maximizing the magnitude and duration of the effect of drug administration would facilitate ascertaining whether the attenuating effect of concurrent activation of PZ Vgat neurons, if any, was partial or complete. It is moreover the case that the effects of modafinil and caffeine are more robust when administered during the sleep period than during the wake period. For example, administration of modafinil (64 mg/kg, i.p.) at the light-dark transition (that is, near or at peak waking drive) produces a rather modest (~30 min or 17%) increase in wakefulness during the 3 h post-injection period (Lin et al, 2008) , whereas administration of modafinil (32 mg/kg, i.p.) during the light period doubles the amount of wakefulness during the 4-h post-injection period (Parmentier et al, 2007) . Also, in our previous work, we showed that activation of PZ GABAergic neurons during the dark (waking) phase enhanced slow-wave-sleep to a greater degree than activation of these neurons during the light (sleep) period (Anaclet et al, 2014) . Hence, our experimental design emphasized a time of day when the effects of the wake-promoting drugs were at or near their maximal effect, whereas the effects of PZ GABA activation was not. As such, any time of day influence should have biased wake, and not sleep, in our experiments. Nevertheless, the timing of drug administration is a critical consideration and could have influenced our results through other mechanisms. For example, the circadian rhythm of dopamine transporter (DAT) activity (Ferris et al, 2014) could have modified the magnitude of armodafinil's wake-promoting action. DAT activity appears to reach a maximum at ZT9-10, 2-3 h before lights-off, and is at a minimum at ZT19-20, during the second half of the dark period (Ferris et al, 2014) . At the time of the injections Parafacial zone GABA neurons actively drive sleep C Anaclet et al in the present study, ZT3, DAT activity appears to be at its mean level of activity. Similarly, the wake-promoting action of caffeine could have time-of-day dependency given that adenosine levels increase in the basal forebrain and the cortex during period of wakefulness and decrease during period of sleep (Kalinchuk et al, 2011) . At ZT3, which is 3 h into the sleep period, adenosine levels would have been elevated, whereas at lights-off adenosine levels would have been low. Given the strong and dose-dependent wakepromoting action of armodafinil and caffeine and the more limited enhancement of sleep following activation of PZ Vgat neurons at ZT3, we are confident that similar, if not more robust, results would have been obtained if the experiments were performed at lights-off.
Activation of PZ Vgat Neurons Completely Blocks the Wake Promoting Action of Armodafinil
Racemic modafinil and its R-enantiomer, armodafinil, are potent wake-promoting drugs used for the treatment of sleepiness in a myriad of disorders (Dell'Osso et al, 2014) . To date, the only mouse model in which modafinil demonstrably failed to induce wakefulness is the dopamine D2 receptor knockout mouse when pretreated with a dopamine D1 receptor antagonist (Qu et al, 2008) , indicating that modafinil wake-promoting action is mediated by dopamine signaling. Here we show, for the first time, that the wakepromoting action of armodafinil can be completely antagonized by activation of a delimited node of medullary GABAergic neurons. We specifically showed that PZ Vgatinduced SWS latency and amount as well as cortical SWA were not diminished by administration of high-dose armodafinil. These results not only emphasize the potent ability of PZ Vgat neurons to produce and maintain sleep, but may also provide new insights into the wake-promoting action of modafinil, something that has remained enigmatic. To this end, modafinil is a DAT inhibitor and available evidence suggests that modafinil enhances wakefulness by increasing dopaminergic transmission (Wisor, 2013) . However, modafinil's inhibitory action on DAT is weak and is unlikely to account in full for its potent wake-promoting action, suggesting additional, unknown mechanisms. The findings from the present study raise the interesting possibility that PZ Vgat neurons may play an important role in modafinil's wake-promoting action. For example, armodafinil may exert its wake-promoting effect through direct inhibition of PZ Vgat neurons. In the present study, PZ Vgat neurons were activated via the hM3Dq receptor and as such any direct inhibitory action of armodafinil on PZ Vgat neurons may have been masked. To test this putative inhibition of PZ Vgat neurons by armodafinil, future studies could be contemplated, in which armodafinil is administered to animals with PZ Vgat lesions, as was previously done with the sleep-promoting ventrolateral preoptic area (Vetrivelan et al, 2014) , or administered to PZ Vgat knockout mice (Anaclet et al, 2012) . Another possibility is that PZ Vgat neurons may strongly inhibit all wake-promoting neurotransmitter systems that are potentiated by modafinil such as histamine, noradrenaline, serotonine, GABA, and glutamate (Gerrard and Malcolm, 2007 Another unexpected finding in our study, in particular as it stands in contrast to previous reports in mouse, cat and human subjects (Buguet et al, 1995; Lin, 2000; Parmentier et al, 2007; Wisor et al, 2006) , was that SWS was increased for about an hour, and REM sleep for about 10 min, during the dark period following the injection (9-21 h post injection) of both armodafinil and CNO+armodafinil, indicating a sleep rebound. These previous studies had found that modafinil did not produce sleep rebound. While it is difficult to explain this discrepancy, it is the case that few studies using modafinil or armodafinil appear to have analyzed the post-injection sleep-wake data for a full 24 h, as we did here. Given the observed sleep rebound in our study, we would argue that armodafinil can influence sleep homeostatic drive.
Activation of PZ
Vgat Neurons Partially Blocks the Wake-Promoting Action of Caffeine Studies in humans have shown that caffeine intake at bed time increases sleep latency, decreases SWS amount and SWA and increases sigma/beta frequencies during SWS (Drapeau et al, 2006; Landolt et al, 1995) . Similar results have been described on recovery sleep when caffeine is administered at the end of a sleep deprivation period (Landolt et al, 2004) . In this study, we show that coinjection of CNO+caffeine significantly increased SWS latency and decreased SWS amount and SWA, as compared with administration of CNO alone. Thus, similar quantitative/qualitative parameters of SWS were observed between control (saline) and CNO+caffeine injections. A parsimonious interpretation of this finding is that caffeine antagonizes PZ Vgat SWS-promoting action and vice versa. It has been suggested that caffeine may promote wakefulness by blocking adenosine-mediated inhibition of basal forebrain (BF) neurons via adenosine A1 receptor (Basheer et al, 2001) . Given that (1) PZ Vgat neurons enhance SWS at least in part by inhibiting parabrachial nucleus → BF → cortex ascending arousal pathway (Anaclet et al, 2014) ; (2) that activation of BF cholinergic neurons can block cortical SWA during SWS, while activation of BF GABAergic neurons strongly enhance cortical desynchronization (Anaclet et al, 2015) ; and (3) increased adenosine concentration in the BF may be the molecular substrate for sleep homeostasis (Porkka-Heiskanen et al, 2000) , we hypothesize that the BF may be a key circuit node for PZ Vgat SWSpromoting action and that PZ Vgat inhibition of the BF could be mediated, at least in part, by adenosine. Given, moreover, that fast cortical EEG frequencies were increased following CNO+caffeine as compared with control injections, it is clear that caffeine is still able to desynchronize the cortical EEG even when PZ Vgat neurons are active. The neuronal substrate of caffeine-induced cortical desynchronization remains to be elucidated but we hypothesize that caffeine may act downstream of PZ Vgat neurons, possibly directly on cortical neurons by blocking neuronal adenosine A1 receptors (Bjorness et al, 2016) or, as previously shown, on adenosine A2A receptors of the nucleus accumbens shell (NAs; (Lazarus et al, 2011) ). Whether or not PZ Vgat neurons influence directly (synaptically) or indirectly (via other synaptic relays), the activity of NAs neurons is currently unknown, but stands to be an exciting area of future investigative work. Finally, and as previously described (Parmentier et al, 2007) , caffeine administration in the present study, even at the lowest dose and combined with CNO, resulted in a sleep rebound during the dark period following injections, substantiating a direct influence of caffeine on sleep homeostatic drive.
In sum, these findings provide the first evidence that activation of PZ GABA-releasing neurons actively maintains SWS and cortical SWA. That the wake-promoting action of two widely used psychostimulants can be counteracted by activation of this delimited sleep-promoting cell population underscores the potency of control that PZ Vgat neurons can exert on neural function, in particular behavioral state control. Outcomes from this study also raise new questions regarding the mechanism of action of armodafinil and suggest a possible shared circuit substrate by which armodafinil and caffeine produce arousal and that PZ Vgat neurons drive and maintain SWS.
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